Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	WYE-125132	1	72	sigmoid	sigmoid	BT20 WYE-132 0 1 72	8	2.067	0.0893	0.289	0.402	0.0435	0.256	1.0	0.987	2.28e-06	NA	0.154	0.403	0.647	0.0353	0.375	0.941	0.985	3.56e-06	NA
BT-20	Alpelisib	1	72	sigmoid	sigmoid	BT20 alpelisib 0 1 72	8	2.077	1.14	0.046	0.196	3.52	-1.0	0.977	0.966	4.1e-05	NA	1.32	0.26	0.825	1.32	0.0	1.13	0.942	0.000194	NA
BT-20	Omipalisib	1	72	sigmoid	sigmoid	BT20 omipalisib 0 1 72	8	2.078	0.00617	-0.729	0.985	0.0283	-0.739	0.596	0.97	2.83e-05	NA	0.00781	0.0157	0.306	0.00685	0.0597	0.96	0.988	1.57e-06	NA
Hs 578T	Omipalisib	1		sigmoid	sigmoid	Hs578T omipalisib 1	8	2.079	0.00552	-0.546	0.842	0.17	-1.0	0.321	0.98	8.1e-06	NA	0.0079	0.0459	0.351	0.0079	0.0	0.369	0.984	4.12e-06	NA
BT-20	Pictilisib	1	72	sigmoid	sigmoid	BT20 pictilisib 0 1 72	8	2.085	1.25	0.163	0.177	5.0	-1.0	0.791	0.994	1.75e-07	NA	1.52	0.323	0.838	1.52	0.0	0.865	0.989	1.22e-06	NA
HCC38	Alpelisib	2	72	flat	flat	HCC38 alpelisib 0 2 72	8	2.086	Inf	0.848	0.0559	0.0	0.848	0.01	-0.0371	1.0	0.931	Inf	0.848	0.944	0.0	0.848	0.01	-0.0359	1.0	0.932
BT-20	MK2206	1	72	sigmoid	sigmoid	BT20 MK-2206 0 1 72	8	2.089	Inf	0.732	0.102	4.16	0.529	0.345	0.671	0.0357	NA	Inf	0.741	0.898	4.14	0.538	0.337	0.676	0.034	NA
HCC38	PI103	2	72	sigmoid	sigmoid	HCC38 PI-103 0 2 72	8	2.094	0.856	0.226	0.167	0.672	0.135	1.3	0.986	2.7e-06	NA	1.04	0.359	0.851	0.488	0.33	1.43	0.981	6.52e-06	NA
Hs 578T	Alpelisib	1		sigmoid	sigmoid	Hs578T alpelisib 1	8	2.097	2.3	0.449	0.205	42.0	-1.0	0.378	0.954	9.56e-05	NA	3.9	0.508	0.803	3.9	0.0	0.401	0.94	0.000216	NA
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
HCC38	Sirolimus	2	72	flat	flat	HCC38 rapamycin 0 2 72	8	2.106	Inf	0.588	0.371	0.0	0.588	0.01	0.496	0.128	0.629	Inf	0.616	0.65	0.0	0.616	0.01	0.246	0.429	0.649
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
BT-20	CAL-101	1	72	flat	flat	BT20 idelalisib 0 1 72	8	2.112	Inf	0.869	0.0546	0.0	0.869	0.01	0.0807	0.777	0.938	Inf	0.867	0.943	0.0	0.867	0.01	0.0778	0.784	0.936
HCC38	TGX221	2	72	sigmoid	sigmoid	HCC38 TGX-221 0 2 72	8	2.116	Inf	0.908	0.0281	4.57	0.803	0.501	0.711	0.0242	NA	Inf	0.905	0.971	4.56	0.797	0.497	0.705	0.0256	NA
BT-20	AZD8055	1	72	sigmoid	sigmoid	BT20 AZD8055 0 1 72	8	2.117	0.0548	0.243	0.465	0.0266	0.213	0.768	0.984	4.08e-06	NA	0.0937	0.365	0.589	0.0198	0.335	0.713	0.982	5.4e-06	NA
HCC38	Dactolisib	2	72	sigmoid	sigmoid	HCC38 dactolisib 0 2 72	8	2.120	0.0118	-0.0557	0.668	0.0118	-0.00134	0.785	0.98	7.61e-06	NA	0.0145	0.204	0.447	0.00701	0.245	0.927	0.988	1.88e-06	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.0	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.0	0.908	0.01	-0.00745	1.0	0.955
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.0	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.0	0.813	0.01	0.383	0.234	0.937
HCC38	AZD8055	2	72	sigmoid	sigmoid	HCC38 AZD8055 0 2 72	8	2.128	0.0616	0.16	0.467	0.045	0.124	0.912	0.993	3.13e-07	NA	0.0875	0.314	0.594	0.0332	0.284	0.869	0.991	6.5e-07	NA
BT-20	Buparlisib	1	72	sigmoid	sigmoid	BT20 buparlisib 0 1 72	8	2.131	0.598	-0.394	0.285	1.19	-0.763	1.35	0.992	4.68e-07	NA	0.663	0.0784	0.766	0.663	0.0	1.49	0.981	7.06e-06	NA
HCC38	AZD-6482	2	72	sigmoid	sigmoid	HCC38 AZD6482 0 2 72	8	2.132	Inf	0.898	0.0351	4.71	0.773	0.497	0.824	0.0055	NA	Inf	0.894	0.963	4.7	0.765	0.492	0.82	0.00588	NA
HCC38	Trametinib	2	72	sigmoid	sigmoid	HCC38 trametinib 0 2 72	8	2.133	0.219	0.267	0.389	0.222	-0.00324	0.424	0.987	2.39e-06	NA	0.391	0.377	0.644	0.127	0.183	0.404	0.988	1.91e-06	NA
HCC38	Torin1	2	72	sigmoid	sigmoid	HCC38 Torin1 0 2 72	8	2.136	0.0241	0.0393	0.573	0.0203	0.0651	0.82	0.995	1.24e-07	NA	0.0309	0.247	0.512	0.013	0.267	0.88	0.996	4.87e-08	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)